DOCSLIB.ORG

The Alfred Medical Research & Education Precinct

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Alfred Medical Research & Education Precinct The Alfred Medical Research & Education Precinct The Alfred Medical Research and Education Precinct Research Report 2008 Vision: to be Australia’s leading centre for clinical research underpinned by excellence in basic research and public health. © Alfred Health 2009 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part of this publication may be reproduced by any process without prior written permission from Alfred Health. Enquiries should be directed to the Manager, Alfred and Baker IDI Research Office. ISSN 1445-8853 CONTENTS It is my pleasure to introduce the Alfred Medical Research and Introduction 1 Education Precinct (AMREP) Research Report for 2008. AMREP The AMREP Council 2 AMREP in 2008/2009 3 is a research and educational partnership between Alfred AMREP’s Research Performance 4 Health, Baker IDI Heart and Diabetes Institute, Burnet Institute, Human Research Ethics 5 Monash University, La Trobe University and Deakin University. Animal Ethics 7 Ian Potter Library 7 This report provides a comprehensive overview of the research New AMREP Core Facilities 8 programs undertaken across all institutions based at AMREP Translating Research into Clinical Practice 9 in 2008. Statistics on a selection of indicators of research Allergy, Immunology and Respiratory Medicine 11 performance, monitored since 1998, are also provided. Anaesthesia and Perioperative Medicine 13 Anatomical Pathology 14 Australian Centre for Blood Diseases 15 Seven years on from its establishment in 2002, AMREP has Australian Centre for Health Innovation 17 expanded enormously, largely as a result of the mergers Baker IDI Heart and Diabetes Institute 18 of AMREP’s two medical research institutes with smaller Burnet Institute 21 Burns 26 institutes. In 2006, the Burnet Institute merged with the Austin Cardiothoracic Surgery 27 Research Institute to become a new larger Burnet Institute, Cardiovascular Medicine 28 and, in 2008, the Baker Institute merged with the International Centre for Obesity Research and Education 30 Clinical Pharmacology 31 Diabetes Institute to become Baker IDI Heart and Diabetes Diagnostic and Interventional Radiology 32 Institute. The additional staff of both enlarged institutes will Emergency and Trauma 33 be accommodated in Stage 2 of The Alfred Centre, which is Endocrinology and Diabetes 34 currently under construction and due for completion in Epidemiology and Preventive Medicine 35 Gastroenterology 37 early 2010. General Surgery 38 Global Health 39 I would like to acknowledge the substantial contribution made Immunology 40 by former Alfred Health Chief Executive Jennifer Williams to Infectious Diseases 42 Intensive Care 44 the advancement and support of research at AMREP and, in Medical Oncology 45 particular, her work (with Steve Wesselingh) in driving the Medicine 46 planning of Stage 2 of The Alfred Centre. Melanoma Service 47 Melbourne Sexual Health Centre 48 National Trauma Research Institute 49 I also wish to acknowledge the contribution of Peter McDonald, Neurosciences 50 Acting Chief Executive, following Jennifer’s departure from Neurosurgery 51 Alfred Health in February 2009 until my recent appointment. Nuclear Medicine 52 Nucleus Network 53 Nursing 54 Andrew Way Nutrition 55 Chief Executive, Alfred Health Occupational Therapy 56 Pathology 57 Chair, AMREP Council Pharmacy 58 Physiotherapy 59 Psychiatry 60 Psychology 62 Radiation Oncology 63 Rehabilitation, Aged and Community Care 64 Renal Medicine 65 Rheumatology 66 Speech Pathology 67 Surgery 67 Women’s Health 69 Internal Grants and Awards 70 Major External Grants 73 Postgraduate Students 87 Publications 95 INTRODUCTION 1 THE AMREP COUNCIL Andrew Way Chair, AMREP Council The AMREP Council has a major governance role in providing the MEMBERSHIP (JULY 2009): infrastructure and environment in which research at AMREP can flourish. Andrew Way (Chair) Representative, Alfred Health The Council comprises two representatives from each of the four original AMREP partners and one from each of the newer partners (Deakin University Hilary Bolton Representative, Baker IDI Heart and Diabetes Institute and La Trobe University). Additional members are the Chief Medical Officer and Chief Nursing Officer, Alfred Health (representing the interface between Professor Mari Botti research and clinical practice), and the chairs of the two campus ethics Representative, Deakin University committees and the AMREP Scientific Advisory Committee. Professor Brendan Crabb Representative, Burnet Institute Following are the major items of business considered by the AMREP Associate Professor Sharon Donovan Council from July 2008 to June 2009: Chief Nursing Officer, Alfred Health • Progress with construction of The Alfred Centre Stage 2 Professor Mark Cooper • Bio21 Research Directors Forum Chair, AMREP Scientific Advisory Committee • Redevelopment of AMREP Animal Services Dr Lee Hamley • Proposal for a new AMREP lecture theatre Chief Medical Officer, Alfred Health • Monash Health Sciences Cluster • Facilities management at AMREP Professor Geoff Head / Dr Raffi Gugasyan Chair, AMREP Animal Ethics Committee • Merger of International Diabetes Institute with the Baker Heart Research Institute Professor Garry Jennings • Centralised multi-site ethical review and Streamlined Ethical Representative, Baker IDI Heart and Diabetes Institute Review Process (SERP) Professor John McNeil • Nucleus Network Chair, The Alfred Human Research Ethics Committee • AMREP’s research performance Professor Mark Hogarth • Annual AMREP Research Report Representative, Burnet Institute • Alfred Health education strategy Professor Graeme Ryan • AMREP imaging consortium Representative, Alfred Health • Code for Responsible Conduct of Research Professor Karen Dodd • New NHMRC funding commencing in 2009 Representative, La Trobe University • Restructure of the Monash University Clinical School • AMREP Global Health Forum Professor Napier Thomson / Professor Hatem Salem Representative, Monash University • Development of Critical Care Network • Launch of new Burnet Institute logo Professor Steve Wesselingh • Centre for Health Innovation agreement Representative, Monash University • Campus wide internet outages • Regular reports from The Alfred Human Research Ethics Committee, IN ATTENDANCE the AMREP Animal Ethics Committee, the AMREP Scientific Advisory Heather Gallichio (Secretary) Committee, AMREP operational working groups and Monash University Manager, Alfred & Baker IDI Research Office Biosafety Committee (on dealings with genetically modified organisms). Gillian Holley Manager, Monash University Central Clinical School Jennifer Williams, former Alfred Health Chief Executive, was Chair of the Bill O’Shea AMREP Council until February 2009 when she left to become Chief Executive Alfred Health Corporate Counsel of the Australian Red Cross Blood Service. Peter McDonald, Acting Chief Executive, chaired the Council from March to June 2009. Geoff McDonald Director, Capital and Infrastructure, Alfred Health Ian Martin General Manager, Infrastructure and Facilities Management, Baker IDI 2 THE AMREP COUNCIL AMREP IN 2008/2009 Professor Graeme Ryan AC Director Research Strategy, Alfred Health Research Performance Strong support from the Deans of Medicine and Health Sciences of Monash and AMREP’s research performance continued to show impressive growth in 2008. La Trobe Universities is shown by their leadership of the newly formed Education Total external research funding increased from $68 million in 2007 to $83 and Research Advisory Committee. Simulation education is highly appreciated million. Of this, almost $39 million came from the NHMRC and the US National at all levels of clinical practice, and significant funding is being allocated under Institutes of Health. The number of masters and doctoral degree completions a new Federal initiative to expand clinical placement options and to support more than doubled from the level in 2007 to 194. Ninety-one of these were education for new graduates. CHI is now well positioned to take a strong role in doctoral degree completions. The number of publications rose from 1028 to developing and evaluating best practice models of simulation education. 1097. Impact factor analysis of published journal articles showed a substantial improvement in quality from the previous year. Appointment of Director, National Trauma Research Institute AMREP researchers were awarded more than $40 million in total direct NHMRC Professor Russell Gruen recently commenced as Director of the National Trauma grant funding commencing in 2009. Highlights were an Australia Fellowship Research Institute. He has also been appointed as Head of Trauma Quality awarded to Professor Mark Cooper (Baker IDI), $23.3 million of new Project Assurance at The Alfred and a Professor of Surgery and Public Health with Grant funding and $520,000 for H1N1 influenza research announced in July Monash University. Professor Gruen is a general surgeon specialising in trauma 2009. care. He was Associate Professor of Surgery at the Royal Melbourne Hospital and the University of Melbourne from 2006. AMREP World Health Day Global Health Forum Global Health and Global Crises was the theme of the 3rd AMREP World Health Professor Gruen’s research expertise includes organisation and evaluation Day Global Health Forum held on 7 April, 2009. More than 250 participants of systems of care, including trauma systems; audit and clinical governance; attended from South Africa, China, Indonesia, Fiji, New Zealand and Australia to
Load more

Recommended publications
  • Governance and Remuneration 2014
    Governance & remuneration reportStrategic In this section Our Board 72 Our Corporate Executive Team 76 Chairman’s letter 78 Corporate governance framework 79 Board report to shareholders Oversight and stewardship in 2014 and future actions 80 remuneration & Governance Leadership and effectiveness 82 Committee reports Audit & Risk 86 Nominations 92 Corporate Responsibility 94 Remuneration report Chairman’s annual statement 96 Annual report on remuneration 97 2014 Remuneration policy report 119 Financial statements Financial Investor information Investor GSK Annual Report 2014 71 Our Board Strategic reportStrategic Diversity Experience International experience Composition Tenure (Non-Executives) % % % % Scientific 19 Global 75 Executive 19 Up to 3 years 39 % % % % Finance 31 USA 100 Non-Executive 81 3-6 years 15 % % % % Industry 50 Europe 94 Male 69 7-9 years 23 % % % EMAP 63 Female 31 Over 9 years 23 Sir Christopher Gent 66 Skills and experience Chairman Sir Christopher has many years of experience of leading global businesses and a track record of delivering outstanding performance Governance & remuneration & Governance Nationality in highly competitive industries. He was appointed Managing Director British of Vodafone plc in 1985 and then became its Chief Executive Officer Appointment date in 1997 until his retirement in 2003. Sir Christopher was also a 1 June 2004 and as Chairman Non-Executive Director of Ferrari SpA and a member of the British on 1 January 2005 Airways International Business Advisory Board. Committee membership External appointments Corporate Responsibility Sir Christopher is a Senior Adviser at Bain & Co. Committee Chairman, Nominations, Remuneration and Finance Sir Philip Hampton 61 Skills and experience Chairman Designate Prior to joining GSK, Sir Philip chaired major FTSE 100 companies including J Sainsbury plc.
    [Show full text]
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • Annual Review 2005
    GS2184_Review_A\W2.qxd 7/3/06 4:58 pm Page fc1 Annual Review 2005 human being Do more, feel better, live longer GS2184_Review_A\W2.qxd 9/3/06 1:28 pm Page ifc2 01 An interview with Sir Christopher Gent, Chairman, and JP Garnier, Chief Executive Officer 05 Tachi Yamada, Chairman, Research & Development, Pharmaceuticals 06 Jean Stéphenne, President and General Manager, GSK Biologicals 08 John Clarke, President, Consumer Healthcare 11 David Stout, President, Pharmaceutical Operations 14 Performance highlights 15 Business operating review 18 The Board 19 The Corporate Executive Team 20 Summary remuneration report 23 Corporate governance 24 Responsibility statements 25 Summary financial statements 26 Summary information under US GAAP 27 Shareholder information 29 Chairman and CEO’s closing letter JP Garnier (left) and Sir Christopher Gent (right) GS2184_Review_A\W2.qxd 7/3/06 5:01 pm Page 01 “Discovering important medicines, eradicating diseases, improving the quality of people’s lives and making medicines available to a greater number of people. This is what we do – and what we do matters to people.” JP Garnier, Chief Executive Officer An interview with Sir Christopher Gent, Chairman and JP Garnier, Chief Executive Officer 2005: a year of success and progress “Thanks to the efforts of our employees around the company’s pipeline is one of the largest and most world, 2005 was a very successful year for GSK,” says promising in the industry, with 149 projects in clinical JP Garnier, Chief Executive Officer. “Not only was it development (as at the end of February 2006), our best year ever from a financial standpoint, we also including 95 new chemical entities (NCEs), 29 product made substantial progress with our pipeline of line extensions (PLEs) and 25 vaccines.
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • 1 Outlook of the Antiviral Drug Era, Now More Than 50 Years After Description of the First Antiviral Drug Erik De Clercq
    j1 1 Outlook of the Antiviral Drug Era, Now More Than 50 Years After Description of the First Antiviral Drug Erik De Clercq 1.1 Introduction: The Prehistory More than 50 years ago, the synthesis of IDU (iododeoxyuridine), a thymidine analogue, was described by Prusoff [1]. This compound would later become the first antiviral drug to be licensed for (topical) use in the treatment of herpes simplex virus (HSV) infections of the eye. In this sense, the advent of IDU marked the birth of the antiviral drug era. There are now about 50 licensed antiviral compounds, half of them are used for the treatment of AIDS, of which the viral origin was first recognized 27 years ago [2, 3] (2008 Nobel Prize for Medicine or Physiology was awarded to Fran¸coise Barre-Sinoussi and Luc Montagnier for their discovery of human immu- nodeficiency virus and to Harald zur Hausen for demonstrating the link between human papilloma virus (HPV) and cervical cancer). Was IDU truly the first antiviral? In retrospect, the antiviral chemotherapy era had a rather slow and unremarkable start. The first compounds quoted to have antiviral activity (against vaccinia virus) were the thiosemicarbazones [4, 5]. These compounds were also found effective against vaccinia virus infection in mice and rabbits [6–8], and one of the thiosemicarbazones, that is, N-methylisatin-b-thiosemicarbazone, even entered clinical studies for the prophylaxis of smallpox [9] just when the smallpox vaccination took over and made any further attempts to develop an antipoxvirus drug apparently superfluous. Then came the benzimidazole derivatives as inhibitors of influenza virus multi- plication [10, 11], but despite the reported effectiveness of the 5,6-dichloro-1-b-D- ribofuranosyl benzimidazole (DRB) [10, 11] against influenza virus multiplication, it was not pursued further as a potential anti-influenza virus agent.
    [Show full text]
  • DNA Methylation Patterns and Cancer
    restriction/modification system, which brought Werner Arber, Daniel Nathans and Hamilton Smith the 1978 Nobel Prize in Physiology or Medicine, and made restriction enzymes the primary tools of Charles Rodolphe Brupbacher Foundation molecular biology. Four decades have passed since then, but the role of 5-methylcytosine in eukaryotic DNA metabolism is still shrouded in mystery. We know that the sperm methylation pattern is largely The erased after fertilization and that methylation is gradually reintroduced Charles Rodolphe Brupbacher Prize during embryogenesis and differentiation, but the processes that for Cancer Research 2017 regulate the cell type- and tissue-specific methylation patterns remain is awarded to to be elucidated. We have also learned that DNA can be not only methylated, but also demethylated, and that aberrant methylation can lead to disease - including cancer. Again, how these processes are regulated remains to be discovered. However, we have learnt a great Sir Adrian Peter Bird, deal about 5-methylcytosine metabolism during the past three decades and much of our knowledge came from the laboratory of Adrian Bird. PhD Adrian spent his doctoral and postdoctoral time in Max Birnstiel’s for his contributions to our understanding laboratory, first in Edinburgh and then in Zurich, studying the amplification of ribosomal DNA in Xenopus laevis. In this organism, of the role of DNA methylation in genomic rDNA in somatic tissues is highly methylated, while the development and disease extrachromosomal amplicons are unmethylated. When he returned to Edinburgh to establish his own group, Adrian set out to study The President The President of the Foundation of the Scientific Advisory Board the methylation pattern of these loci using the newly-available methylation-sensitive restriction enzymes.
    [Show full text]
  • FULL BOARD MEETING September 26, 2019, 8:30AM Chancellor's
    FULL BOARD MEETING September 26, 2019, 8:30AM Chancellor’s Ballroom, Carolina Inn OPEN SESSION 1. Convene Meeting 2. Roll Call 3. Consent Agenda a. Approval of July 31-August 1, 2019 Minutes (Regular Meeting) b. Ratification of Mail Ballot dated June 6, 2019 c. Ratification of Mail Ballot dated August 13, 2019 d. Ratification of Mail Ballot dated September 12, 2019 4. Chair’s Remarks 5. Student Body President’s Remarks 6. Chancellor’s Remarks 7. Environment, Ecology, and Energy Program – Dr. Jaye Cable, Senior Associate Dean for Natural Sciences and Mathematics and Professor, Department of Marine Sciences, & Dr. Paul Leslie, Chair, Environment and Ecology and Pardue Distinguished Professor, Department of Anthropology 8. UNC Policy Collaboratory – Dr. Jeff Warren, Research Director 9. Report of the External Relations Committee 10. Report of the Finance, Infrastructure & Audit Committee 11. Report of the University Affairs Committee CLOSED SESSION 12. *Report of the University Affairs Committee 13. *Legal Update OPEN SESSION 14. Report of the University Affairs Committee 15. Adjournment *Some of the business to be conducted is authorized by the N.C. Open Meetings Law to be conducted in closed session. BOARD OF TRUSTEES MEETING The University of North Carolina at Chapel Hill August 1, 2019 The Board of Trustees met in regular session on Thursday, August 1, 2019 at The Carolina Inn, Chancellor’s Ballroom. Chair Stevens convened the meeting at 8:32 a.m. ROLL CALL Trustee Artis Neal called the roll and the following members were present: Teresa Artis Neal Ashton B. Martin David L. Boliek, Jr. Allie Ray McCullen Jefferson W.
    [Show full text]
  • View Annual Report
    Connecting... Annual Report 2001 Mission Our global quest is to improve the quality of human life by enabling people to do more, feel better and live longer. Our Spirit We undertake our quest with the enthusiasm of entrepreneurs, excited by the constant search for innovation. We value performance achieved with integrity. We will attain success as a world class global leader with each and every one of our people contributing with passion and an unmatched sense of urgency. Strategic Intent We want to become the indisputable leader in our industry. GlaxoSmithKline plc is an English public limited company. Its shares are listed on the London Stock Exchange and the New York Stock Exchange. GlaxoSmithKline plc acquired Glaxo Wellcome plc and SmithKline Beecham plc on 27th December 2000 by way of a scheme of arrangement for the merger of the two companies which became effective on 27th December 2000. This report is the Annual Report of GlaxoSmithKline plc for the year ended 31st December 2001. It comprises in a single document the Annual Report of the company in accordance with United Kingdom requirements and the Annual Report on Form 20-F to the Securities and Exchange Commission in the United States of America. A summary report on the year, the Annual Review 2001, intended for the investor not needing the full detail of the Annual Report, is produced as a separate document. The Annual Review includes the joint statement by the Chairman and Chief Executive Officer, a summary review of operations, summary financial statements and a summary remuneration report. The Annual Review is issued to all shareholders.
    [Show full text]
  • Investor Information 2014
    Investor information reportStrategic In this section Quarterly trend 218 Five year record 222 Product development pipeline 225 Products, competition and intellectual property 229 Risk factors 232 Share capital and share price 242 remuneration & Governance Dividends 244 Tax information for shareholders 244 Annual General Meeting 2015 245 US law and regulation 247 Shareholder services and contacts 249 Glossary of terms and index 251 Financial statementsFinancial Investor information Investor GSK Annual Report 2014 217 Financial record Strategic reportStrategic Quarterly trend An unaudited analysis of the Group results is provided by quarter in Sterling for the financial year 2014. Income statement – total 12 months 2014 Q4 2014 £m CER% £% £m CER% £% Turnover – Pharmaceuticals and Vaccines 18,670 (6) (12) 5,070 (7) (10) – Consumer Healthcare 4,336 (11) (18) 1,116 (7) (10) Total turnover 23,006 (7) (13) 6,186 (7) (10) Cost of sales (7,323) (11) (15) (2,029) (18) (20) Selling, general and administration (8,246) 4 (3) (2,207) 4 – Research and development (3,450) (8) (12) (979) (7) (9) Royalty income 310 (18) (20) 67 (31) (32) Other operating income (700) (347) Operating profit 3,597 (40) (49) 691 (69) (72) Governance & remuneration & Governance Net finance costs (659) (171) Profit on disposal of interest in associates and joint ventures – – Share of after tax profits of associates and joint ventures 30 11 Profit before taxation 2,968 (46) (55) 531 (77) (79) Taxation (137) 494 Tax rate % 4.6% (93.0)% Profit after taxation for the period 2,831 (41) (50)
    [Show full text]
  • GSK Annual Report 2002
    The Impact of Medicines Do more, feel better, live longer Annual Report 2002 www.gsk.com Mission Our global quest is to improve the quality of human life by enabling people to do more, feel better and live longer. Our Spirit We undertake our quest with the enthusiasm of entrepreneurs, excited by the constant search for innovation. We value performance achieved with integrity. We will attain success as a world class global leader with each and every one of our people contributing with passion and an unmatched sense of urgency. Strategic Intent We want to become the indisputable leader in our industry. GlaxoSmithKline plc is an English public limited company. Its shares are listed on the London Stock Exchange and the New York Stock Exchange. GlaxoSmithKline plc acquired Glaxo Wellcome plc and SmithKline Beecham plc on 27th December 2000 by way of a scheme of arrangement for the merger of the two companies which became effective on 27th December 2000. This report is the Annual Report of GlaxoSmithKline plc for the year ended 31st December 2002. It comprises in a single document the Annual Report of the company in accordance with United Kingdom requirements and the Annual Report on Form 20-F to the Securities and Exchange Commission in the United States of America. A summary report on the year, the Annual Review 2002, intended for the investor not needing the full detail of the Annual Report, is produced as a separate document. The Annual Review includes the joint statement by the Chairman and the Chief Executive Officer, a summary review of operations, summary financial statements and a summary remuneration report.
    [Show full text]
  • 6/28/18 PERSONAL: Office Address: the University of Michigan College of Pharmacy 428 Church Street – Room 4002A Ann Arbor
    6/28/18 CURRICULUM VITAE GORDON L. AMIDON PERSONAL: Office Address: The University of Michigan College of Pharmacy 428 Church Street – Room 4002A Ann Arbor, Michigan 48109-1065 Ph: 734-764-2226/ Fax: 734-764-6282 E-mail: [email protected] Birth Date: April 27, 1944 EDUCATION 1967 B.S. Pharmacy, State University of New York at Buffalo, Buffalo, NY. 1970 M.A. Mathematics, The University of Michigan, Ann Arbor, MI. 1971 Ph.D. Pharmaceutical Chemistry, The University of Michigan, Ann Arbor, MI. PROFESSIONAL APPOINTMENTS 1996 (Apr-May) Visiting Professor, ETH Zurich, Department of Pharmacy, Zurich, Switzerland 1994 - present Charles R. Walgreen, Jr., Professor of Pharmacy, College of Pharmacy, The University of Michigan, Ann Arbor, MI. 1994 - present Chairman and Chief Scientific Officer, TSRL, Inc., Ann Arbor, MI 1990 - 1991 Sabbatical Leave from The University of Michigan. Food and Drug Administration, Rockville, MD and University of California San Francisco, San Francisco, CA. 1986 - 1994 President, TSRL, Inc., Ann Arbor, MI 1983 - present Professor of Pharmaceutics, The University of Michigan, College of Pharmacy Ann Arbor, MI 1983 - 1986 Director of Research, SmithKline Consumer Products, Philadelphia, PA 1981 - 1983 Director, Pharmaceutical Chemistry Research, INTERx Research Corp., a subsidiary of Merck & Co., Inc., Lawrence, KS 1981 - 1983 Adjunct Professor of Pharmaceutics, University of Kansas, Department of Pharmaceutical Sciences, Lawrence, KS 2 1976 - 1981 Assoc. Professor, University of Wisconsin, School of Pharmacy, Madison,
    [Show full text]
  • 2013 Annual Review
    2 013 Annual Review About the Society Contents The British Pharmacological Society (BPS) is the primary UK learned society Message from our President and Chief Executive 2 concerned with research into drugs and the way they work. Our members 2013 in numbers 4 work in academia, industry, regulatory agencies and the health services, and many are medically qualified. The Society covers the whole spectrum Member engagement 6 of pharmacology, including laboratory, clinical, and toxicological aspects. Public benefit 19 Promoting pharmacology 30 BPS exists to promote and advance pharmacology (including, without limit, Looking ahead 53 clinical pharmacology) and to be the leading Society for the presentation, promotion, and discussion of all matters relating to both pharmacology and Financials 58 clinical pharmacology and therapeutics (CPT). Specifically, the Society is concerned with the discovery, mechanism of action, use and safety of drugs in humans and animals, in order to contribute to education and the understanding and relief of suffering. 2 / Annual Review Annual Review / 1 Message from our President and Chief Executive 2013 represented an exciting year in the and Putting UK Pharmacology on the Map. Five individuals were inducted into for a further nine meetings. Our Policy, Public Engagement and Outreach work Our commitment to exploring and supporting open access journals and data growth of the Society. Our first five-year Strategy the Hall of Fame at our inaugural Fellow’s Reception in September, while BPS resulted in us attending numerous science festivals and arranging presentations can be found in the Concise Guide to PHARMACOLOGY, which is available provided structure and direction to BPS activities, used its first Parliamentary Reception in December to recognize the winners of across the UK, along with several parliamentary events in Westminster during free online.
    [Show full text]